Hello Everyone,
We have had the good fortune of being able to throw some real explosive profiles in front of you as of late.
We have been seeing some of these small cap companies take off without notice, mirroring a fraction of the volatility that we have been seeing on the crypto markets.
It is highly unusual to profile a 180% winner and a 350% winner back to back.
Don't say I never got you anything for Christmas.
We have a new profile that we want you to research for Thursday's session.
You are definitely going to remember this one if you have been a member since the beginning of the year.
This is a company we showed you back in May when it was all the way down at 1.80 the session we asked you to research them. We also brought it to your attention back in mid-June when it was around 2.50.
By mid June NNVC went on a major run, closing green 6 session in a row and exploding all the way to 3.59 for a pure DOUBLE from our first emails in May and 45% in just 3 sessions from our emails in early June.
NNVC certainly had incredible run in early 2024 and has been building a lot of support around it's current levels.
NanoViricides, Inc. (NYSE American: NNVC) looks well-positioned to be a market disruptor with nontoxic, effective antiviral therapies based on patented nanomedicine technology.
NanoViricides, Inc. (NYSE American: NNVC) is a global leader in the application of nanomedicine technologies to the safe and effective treatment of viruses and their variants INCLUDING drugs against Covid-19, RSV and other respiratory viruses!
Even with a decline since 2022, COVID-19 continues to hospitalize and kill people in the USA – the CDC website states 69,200 hospitalizations and 2,652 deaths since January 1, 2024; the worldwide market size for COVID-19 therapeutics is expected to exceed $16.2 Billion in 2031.
NANOVIRICIDES are better because they destroy viruses and their variants without relying on the patient's immune system, thereby making them effective for populations that include geriatric and pediatric patients.
Antibodies only bind by two points to the virus, and destruction of the complex requires effective immune function, which is not the case in sick patients..
Vaccines only train the body into producing antibodies against the virus in the vaccine. Antibodies and vaccines are easily overcome by viruses by mutating in the field, hence the need for annual influenza vaccine updates.
NV-387 - A novel broad-spectrum antiviral
NanoViricides, Inc. (NYSE American: NNVC)'s lead drug candidate NV-387 (drug product NV-CoV-2), a drug that treats RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections as well as Monkey-pox, has successfully completed Phase 1 clinical trials in healthy subjects with no reported adverse events, even at the highest and repeated dosages. Remarkably, NNVC has been able to develop NV-387 for oral administration already, as well as for injectable and inhalation formulations to enable many modes of use. The Company is currently focused on advancing NV-387 into Phase II human clinical trials for the treatment of RSV infection.
Susceptible viruses CANNOT escape NV-387, even as they continue to evolve in the field into variants. Why? Because no matter how much the virus changes, it continues to use the same host-side signature to bind to and cause infection in the hosts, and thus the nanoviricide would be anticipated to continue to be effective even as the virus mutates to generate variants.
Thus NV-387 and other antiviral drugs designed on the nanoviricides platform can be expected to have decades of effective usability against the target viruses similar to the life of current antibiotics against bacterial infections but in stark contrast to current antiviral approaches.
A broad-spectrum antiviral drug such as NV-387 would be a highly desirable drug globally because it would enable treatment by physicians of patients as soon as they present symptoms of a viral disease without waiting for a test to identify a specific type of viral infection. This is reminiscent of how antibiotics are prescribed, without specific infectious agent identification, relying on the ultra-broad-spectrum of the drug.
NV-387's Extremely Broad Antiviral is a Host Mimetic That Acts As a Decoy To Attract And Trap Many Diverse Viruses, Preventing the Virus from Replication and Reinfection of Other Cells
Over 90% of human pathogenic viruses are known to use one or more "landing sites" that are in the Sulfated Proteoglycans ("SPG") family. A successful host-mimetic nanoviricide drug using SPG as the key feature to attract viruses could theoretically be able to attack most if not all such viruses.
NV-387 is designed to mimic SPG and attack the virus as a cell-mimicking decoy. We have accumulated substantial evidence that in lethal viral infection animal studies, NV-387 demonstrated strong antiviral activity against a range of different virus families, exceeding or matching the activity of known approved drug agents.
ليست هناك تعليقات:
إرسال تعليق